Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
Champions Oncology (NYSE: CSBR) will report third-quarter results for the period ended January 31, 2026, on Thursday, March 12, 2026, after market close.
Rhea-AI Summary
Champions Oncology (NYSE: CSBR) will report third-quarter results for the period ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call the same day at 4:30 P.M. EDT (1:30 P.M. PDT).
Dial-in details: Domestic 888-506-0062, International 973-528-0011, access code 957548. A replay is available for 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode 53731, or via the investors section of the company website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CSBR
On Mar 6, the first trading day after this news, CSBR closed 2.44% above the previous close.
Data tracked by StockTitan Argus for the Mar 6 session.
Key Figures
- Quarter end date
- January 31, 2026
- Third quarter fiscal period to be reported
- Earnings release date
- March 12, 2026
- Q3 FY2026 results to be reported after market close
- Conference call time
- 4:30 P.M. EDT
- Start time for Q3 FY2026 earnings call
- Domestic dial-in
- 888-506-0062
- U.S. access number for earnings conference call
- International dial-in
- 973-528-0011
- Non-U.S. access number for earnings conference call
Previous Earnings date Reports
-
Announced date and call details for Q2 FY2026 results release.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 957548. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 53731, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.